BeiGene, a Chinese biotech developing immunotherapies based on kinase inhibitors, announced terms for its IPO on Tuesday. The Beijing, China-based company plans to raise $126.5 million by offering 5.5 million ADSs at a price range of $22 to $24. Insiders...read more
Yield IPOs yielded disappointing returns while biotech performance was anemic.
13 companies were added to the IPO calendar - including 7 in the health care sector - making this an...read more
Blueprint Medicines, a preclinical biotech developing kinase inhibitors for cancer and genetic diseases, raised $147 million by offering 8.1 million shares (upsized from 7.2 million shares) at $18, above the range of $15 to $17. Blueprint Medicines plans to list...read more
Chinese immunotherapy biotech BeiGene sets terms for $127 million IPO
BeiGene, a Chinese biotech developing immunotherapies based on kinase inhibitors, announced terms for its IPO on Tuesday. The Beijing, China-based company plans to raise $126.5 million by offering 5.5 million ADSs at a price range of $22 to $24. Insiders...read more
US IPO Weekly Recap: 4 IPOs offer dividends and drugs
Yield IPOs yielded disappointing returns while biotech performance was anemic. 13 companies were added to the IPO calendar - including 7 in the health care sector - making this an...read more
Blueprint Medicines prices upsized IPO at $18, above the range
Blueprint Medicines, a preclinical biotech developing kinase inhibitors for cancer and genetic diseases, raised $147 million by offering 8.1 million shares (upsized from 7.2 million shares) at $18, above the range of $15 to $17. Blueprint Medicines plans to list...read more
Week ahead: 6 IPOs planned for the week of Apr 27
Up to six companies could price their IPOs this week. All are either LPs or health care companies (including three biotechs). ...read more